Breaking News

Cellipont Receives Investment from OrbiMed for Commercial Manufacturing Facility

New facility in Texas will have capabilities for process and analytical development and manufacturing services for CAR-T, IPSC, MSC and cell therapies.

Cellipont Bioservices, a cell therapy contract development and manufacturing organization (CDMO), announced a strategic debt facility investment from OrbiMed, a healthcare investment firm. The investment will be used by Cellipont to fully finance the previously announced state-of-the-art commercial facility for cell therapies and gene-modified cell therapies in The Woodlands, TX. “We are energized by this partnership with OrbiMed, which helps us to bring this world-class facility to ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters